At the time of writing, Nautilus Biotechnology Inc [NAUT] stock is trading at $0.93, up 28.22%. An important factor to consider is whether the stock is rising or falling in short-term value. The NAUT shares have gain 38.79% over the last week, with a monthly amount glided 17.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nautilus Biotechnology Inc [NASDAQ: NAUT] stock has seen the most recent analyst activity on December 05, 2024, when Goldman downgraded its rating to a Sell but kept the price target unchanged to $1.75 for it. Previously, Guggenheim started tracking the stock with Buy rating on June 27, 2024, and set its price target to $6. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $8 on January 06, 2022. Cowen initiated its recommendation with a Outperform. Goldman started tracking with a Neutral rating for this stock on August 04, 2021, and assigned it a price target of $10. In a note dated July 13, 2021, Jefferies initiated an Buy rating and provided a target price of $13 on this stock.
For the past year, the stock price of Nautilus Biotechnology Inc fluctuated between $0.66 and $3.09. Currently, Wall Street analysts expect the stock to reach $2.5 within the next 12 months. Nautilus Biotechnology Inc [NASDAQ: NAUT] shares were valued at $0.93 at the most recent close of the market. An investor can expect a potential return of 168.82% based on the average NAUT price forecast.
Analyzing the NAUT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.32 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7744 points at the first support level, and at 0.6218 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0448, and for the 2nd resistance point, it is at 1.1626.
Ratios To Look Out For
It is important to note that Nautilus Biotechnology Inc [NASDAQ:NAUT] has a current ratio of 17.36. On the other hand, the Quick Ratio is 17.36, and the Cash Ratio is 4.08.
Transactions by insiders
Recent insider trading involved Mallick Parag, Chief Scientist, that happened on May 08 ’25 when 12000.0 shares were purchased. Chief Scientist, Mallick Parag completed a deal on May 12 ’25 to buy 1500.0 shares. Meanwhile, CEO, President, and Secretary Patel Sujal M bought 53300.0 shares on Mar 19 ’25.
